2 Information about bimekizumab

Marketing authorisation indication

2.1 Bimekizumab (Bimzelx, UCB Pharma) is indicated for the treatment of 'adults with active psoriatic arthritis who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs)'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for bimekizumab.


2.3 The list price of bimekizumab is £2,443 per 320 mg (two 160 mg prefilled syringes or two 160 mg prefilled pens) dose (excluding VAT; BNF online accessed August 2023).

2.4 The company has a commercial arrangement. This makes bimekizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)